X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs DIVIS LABORATORIES - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA DIVIS LABORATORIES GSK PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 67.6 32.5 208.1% View Chart
P/BV x 13.6 5.8 234.0% View Chart
Dividend Yield % 1.1 0.9 124.3%  

Financials

 GSK PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
DIVIS LABORATORIES
Mar-17
GSK PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,7601,222 225.9%   
Low Rs2,040784 260.2%   
Sales per share (Unadj.) Rs339.0153.1 221.4%  
Earnings per share (Unadj.) Rs41.439.9 103.7%  
Cash flow per share (Unadj.) Rs45.944.6 102.9%  
Dividends per share (Unadj.) Rs35.0010.00 350.0%  
Dividend yield (eoy) %1.51.0 146.3%  
Book value per share (Unadj.) Rs242.9201.8 120.4%  
Shares outstanding (eoy) m84.70265.47 31.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.16.6 108.1%   
Avg P/E ratio x57.925.1 230.8%  
P/CF ratio (eoy) x52.322.5 232.4%  
Price / Book Value ratio x9.95.0 198.8%  
Dividend payout %84.525.0 337.6%   
Avg Mkt Cap Rs m203,280266,266 76.3%   
No. of employees `000NA9.7 0.0%   
Total wages/salary Rs m5,2344,687 111.7%   
Avg. sales/employee Rs ThNM4,175.0-  
Avg. wages/employee Rs ThNM481.5-  
Avg. net profit/employee Rs ThNM1,089.3-  
INCOME DATA
Net Sales Rs m28,71540,643 70.6%  
Other income Rs m545749 72.8%   
Total revenues Rs m29,26041,392 70.7%   
Gross profit Rs m5,05914,460 35.0%  
Depreciation Rs m3801,233 30.8%   
Interest Rs m223 8.8%   
Profit before tax Rs m5,22213,953 37.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,8923,349 56.5%   
Profit after tax Rs m3,50810,604 33.1%  
Gross profit margin %17.635.6 49.5%  
Effective tax rate %36.224.0 150.9%   
Net profit margin %12.226.1 46.8%  
BALANCE SHEET DATA
Current assets Rs m21,81540,105 54.4%   
Current liabilities Rs m15,9996,595 242.6%   
Net working cap to sales %20.382.5 24.6%  
Current ratio x1.46.1 22.4%  
Inventory Days Days64119 53.6%  
Debtors Days Days1981 23.2%  
Net fixed assets Rs m12,47519,995 62.4%   
Share capital Rs m847531 159.5%   
"Free" reserves Rs m19,72653,043 37.2%   
Net worth Rs m20,57353,574 38.4%   
Long term debt Rs m60-   
Total assets Rs m39,47561,585 64.1%  
Interest coverage x2,612.0618.4 422.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.7 110.2%   
Return on assets %8.917.3 51.5%  
Return on equity %17.119.8 86.1%  
Return on capital %26.226.1 100.6%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m56435,384 1.6%   
Fx outflow Rs m7,42910,399 71.4%   
Net fx Rs m-6,86524,985 -27.5%   
CASH FLOW
From Operations Rs m4,72811,493 41.1%  
From Investments Rs m-1,042-11,372 9.2%  
From Financial Activity Rs m-3,066-93 3,293.7%  
Net Cashflow Rs m62028 2,182.0%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 11.8 86.4%  
FIIs % 23.8 19.0 125.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.2 89.5%  
Shareholders   102,036 31,796 320.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

GSK PHARMA at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

Aug 17, 2018 | Updated on Aug 17, 2018

GSK PHARMA share price has hit a 52-week high. It is presently trading at Rs 3,350. BSE 500 Index is up by 0.8% at 15,497. Within the BSE 500, GSK PHARMA (up 2.0%) and IL&FS TRANSPORTATION (up 8.0%) are among the top gainers, while top losers are TECHNO ELECTRIC and P&G HYGIENE.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - TORRENT PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS